These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37300743)

  • 1. Post-Marketing Safety Surveillance of Quadrivalent Influenza Vaccine (VaxigripTetra) in Children Aged 6 to 35 Months in South Korea.
    Choe S; Talanova O; Shin S; Syrkina O; Fournier M
    Infect Dis Ther; 2023 Jun; 12(6):1715-1723. PubMed ID: 37300743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-marketing Surveillance of a Quadrivalent Influenza Vaccine (Vaxigrip Tetra) in South Korea.
    Lim S; Li X; Syrkina O; Fournier M
    Infect Dis Ther; 2022 Oct; 11(5):2035-2043. PubMed ID: 36070176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014-2022) Following the Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged 6 Months and Older.
    Dos Santos G; Devadiga R; Kim CS; Bang J
    Drug Saf; 2024 Apr; 47(4):365-375. PubMed ID: 38483767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
    Choi WS; Noh JY; Song JY; Cheong HJ; Wie SH; Lee JS; Lee J; Kim SW; Jeong HW; Jung SI; Kim YS; Woo HJ; Kim KH; Kim H; Kim WJ
    Hum Vaccin Immunother; 2017 Jul; 13(7):1653-1660. PubMed ID: 28406746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-Marketing Safety Surveillance of a Childhood Pentavalent Diphtheria-Tetanus-Acellular Pertussis-Polio and Haemophilus influenzae Type B (DTaP-IPV//Hib) Vaccine in South Korea.
    Yang K; Kim H; Ortiz E; Huoi C; Kang J
    Infect Dis Ther; 2023 Feb; 12(2):499-511. PubMed ID: 36520326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-Marketing Surveillance of Tetravalent Diphtheria-Tetanus-Acellular Pertussis and Inactivated Poliovirus (DTaP-IPV) Vaccine in South Korea, 2009 to 2015.
    Choe YJ; Vidor E; Manson C
    Infect Dis Ther; 2022 Aug; 11(4):1479-1492. PubMed ID: 35575974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
    Izikson R; Brune D; Bolduc JS; Bourron P; Fournier M; Moore TM; Pandey A; Perez L; Sater N; Shrestha A; Wague S; Samson SI
    Lancet Respir Med; 2022 Apr; 10(4):392-402. PubMed ID: 35114141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results from a large post-marketing safety surveillance study in the Republic of Korea with a quadrivalent meningococcal CRM-conjugate vaccine in individuals aged 2 months-55 years.
    Yoo BW; Jung HL; Byeon YS; Han DK; Jeong NY; Curina C; Moraschini L; Kim SJ; Bhusal C; Pellegrini M; Miao Y
    Hum Vaccin Immunother; 2020 Jun; 16(6):1260-1267. PubMed ID: 31634044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active-controlled phase III study of an egg-cultivated quadrivalent inactivated split-virion influenza vaccine (GC3110A) in healthy Korean children aged 6-35 months.
    Choi UY; Kim KH; Lee KY; Kim JH; Kim CS; Eun BW; Kim HM; Kim DH; Song SE; Jo DS; Lee J; Ma SH; Kim KN; Kang JH
    Vaccine; 2021 Apr; 39(15):2103-2109. PubMed ID: 33736920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
    Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
    Greenberg DP; Robertson CA; Noss MJ; Blatter MM; Biedenbender R; Decker MD
    Vaccine; 2013 Jan; 31(5):770-6. PubMed ID: 23228813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized, Double-blind, Active-controlled Phase III Trial of a Cell Culture-derived Quadrivalent Inactivated Influenza Vaccine in Healthy South Korean Children and Adolescents 6 Months to 18 Years of Age.
    Eun BW; Lee TJ; Lee J; Kim KH; Kim DH; Jo DS; Shin SH; Kim H; Kim KH; Kim YK
    Pediatr Infect Dis J; 2019 Sep; 38(9):e209-e215. PubMed ID: 31335572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-Marketing Surveillance of Adverse Events Following Vaccination with the Live-Attenuated Japanese Encephalitis Chimeric Virus Vaccine (Imojev
    Kim HS; Oh Y; Korejwo J; Castells VB; Yang K
    Infect Dis Ther; 2020 Sep; 9(3):589-598. PubMed ID: 32474892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD® and VANTAFLU® in South Korean Subjects Aged ≥65 Years.
    Yoo BW; Kim CO; Izu A; Arora AK; Heijnen E
    Infect Chemother; 2018 Dec; 50(4):301-310. PubMed ID: 30600653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of a quadrivalent influenza vaccine in Vietnamese healthy subjects aged 6 months and older.
    Thiem VD; Chabanon AL; Fournier M; Lavis N; Quang ND; Ha VH; Sanicas M
    Hum Vaccin Immunother; 2021 Mar; 17(3):690-693. PubMed ID: 32783746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-Marketing Surveillance Observational Study of Quadrivalent Meningococcal Diphtheria Toxoid Conjugate Vaccine (MenACWY-DT, MCV4/Menactra
    Kim HS; Engel S; Neveu D; Thollot Y; Oster P; Yang K
    Infect Dis Ther; 2021 Mar; 10(1):399-409. PubMed ID: 33439463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety Profile of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season.
    Salamanca de la Cueva I; Cinconze E; Eckermann T; Nwoji U; Godderis L; Lu E; Martínez-Gómez X; Wang H; Yanni E
    Drug Saf; 2021 Dec; 44(12):1375-1390. PubMed ID: 34694589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-Marketing Surveillance of Hepatitis A Virus Vaccine (Avaxim
    Kim H; Oh Y; Thollot Y; Bravo C
    Infect Dis Ther; 2019 Mar; 8(1):105-112. PubMed ID: 30673992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-marketing surveillance study of the safety of the HPV-16/18 vaccine in Korea (2017-2021).
    Eun BW; Bahar E; Xavier S; Kim H; Borys D
    Hum Vaccin Immunother; 2023 Dec; 19(1):2184756. PubMed ID: 36896702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of Quadrivalent Influenza HA vaccine in Indonesian children: An open-labeled, bridging, clinical study.
    Dhamayanti M; Tarigan R; Fadlyana E; Prasetyo D; Amalia N; Rusmil VK; Sari RM; Bachtiar NS; Rusmil K; Kartasasmita CB
    Vaccine; 2020 Jan; 38(5):993-1000. PubMed ID: 31862195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.